April 23, 2020 / 10:03 AM / a month ago

BRIEF-United Therapeutics Announces Additional Results From Freedom-Ev Study Showing Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

April 23 (Reuters) - United Therapeutics Corp:

* UNITED THERAPEUTICS ANNOUNCES ADDITIONAL RESULTS FROM FREEDOM-EV STUDY SHOWING THE HEMODYNAMIC AND RISK STATUS REDUCTION BENEFITS OF ORENITRAM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

* UNITED THERAPEUTICS CORP - ORENITRAM DEMONSTRATED IMPROVEMENT IN HEMODYNAMIC PARAMETERS AND RISK STATUS

* UNITED THERAPEUTICS CORP - TREATMENT WITH ORENITRAM RESULTED IN SIGNIFICANT CHANGES IN HEMODYNAMIC PARAMETERS AT WEEK 24 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below